Belite Bio

About:

Belite Bio is a clinical stage biopharmaceutical drug development company.

Website: https://www.belitebio.com

Description:

Belite Bio focused on first-in-class therapeutics targeting untreatable inherited orphan diseases and age-related metabolic diseases, including atrophic age-related macular degeneration, stargardt disease, and nonalcoholic steatohepatitis. They develop anti-RBP4 therapies to treat age-related metabolic diseases, including macular degeneration, liver disease, and diabetes. Their technology platform effectively reduces circulating levels of RBP4, a vitamin A transporter protein linked to the development of aging metabolic diseases, including dry age-related macular degeneration, liver disease, and diabetes.

Total Funding Amount:

$83.8M

Estimated Revenue Range:

$1B to $10B

Headquarters Location:

San Diego, California, United States

Founded Date:

2018-01-01

Founders:

Number of Employees:

11-50

Last Funding Date:

2024-11-03

IPO Status:

Public

Industries:

© 2025 bioDAO.ai